HT-55Homo sapiens (Human)Cancer cell line

Also known as: HT55

🤖 AI SummaryBased on 13 publications

Quick Overview

Human colorectal cancer cell line with known genetic alterations

Detailed Summary

HT-55 is a human colorectal cancer cell line derived from a primary tumor. It exhibits specific genetic alterations, including mutations in the mismatch repair (MMR) pathway, which are associated with microsatellite instability (MSI). These genetic features make HT-55 a valuable model for studying the molecular mechanisms of colorectal cancer, particularly in the context of drug response and therapeutic resistance. The cell line has been used in studies to investigate the relationship between genetic mutations and sensitivity to chemotherapeutic agents, such as 5-fluorouracil (5-FU). HT-55's genetic profile also contributes to its utility in understanding the role of MSI in cancer progression and treatment outcomes.

Research Applications

Molecular and pharmacological studies of colorectal cancerInvestigation of microsatellite instability (MSI) and mismatch repair (MMR) defectsDrug sensitivity and resistance profilingGenomic and transcriptomic analysis of cancer cell lines

Key Characteristics

Presence of microsatellite instability (MSI)Mutations in mismatch repair (MMR) pathway genesRelevance to 5-fluorouracil (5-FU) responseUtilized in studies of colorectal cancer molecular subtypes
Generated on 6/16/2025

Basic Information

Database IDCVCL_1294
SpeciesHomo sapiens (Human)
Tissue SourceRectum[UBERON:UBERON_0001052]

Donor Information

Age CategoryUnknown
SexUnknown

Disease Information

DiseaseRectal adenocarcinoma
LineageBowel
SubtypeColon Adenocarcinoma
OncoTree CodeCOAD

DepMap Information

Source TypeECACC
Source IDACH-000926_source

Known Sequence Variations

TypeGene/ProteinDescriptionZygosityNoteSource
MutationSimpleTP53p.Arg213Leu (c.638G>T)Unspecified-Unknown
MutationSimpleDNMT3Ap.Lys241Ter (c.721A>T)Heterozygous-Unknown
MutationSimpleBRAFp.Asn581Tyr (c.1741A>T)Unspecified-Wistar
MutationSimpleAPCp.Arg1463Ser (c.4389A>T)Heterozygous-Unknown, PubMed=24755471
MutationSimpleAPCp.Gln1303Ter (c.3907C>T)Unspecified-PubMed=28179481
MutationSimpleAPCp.Gln1131Ter (c.3391C>T)Heterozygous-Unknown, PubMed=24755471

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin
X
CSF1PO
11
D13S317
9,13
D16S539
14
D18S51
13
D21S11
28
D3S1358
15,18
D5S818
11,12
D7S820
11,13
D8S1179
11,14
FGA
24
Penta D
11
Penta E
7,8
TH01
8,9.3
TPOX
8,9
vWA
14,17
Gene Expression Profile
Gene expression levels and statistical distribution
Loading cohorts...
Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Pan-cancer proteomic map of 949 human cell lines.";

Robinson P.J., Zhong Q., Garnett M.J., Reddel R.R.

Cancer Cell 40:835-849.e8(2022).

Quantitative proteomics of the Cancer Cell Line Encyclopedia.";

Sellers W.R., Gygi S.P.

Cell 180:387-402.e16(2020).

Comprehensive transcriptomic analysis of cell lines as models of primary tumors across 22 tumor types.

van 't Veer L.J., Butte A.J., Goldstein T., Sirota M.

Nat. Commun. 10:3574.1-3574.11(2019).

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

Differential effector engagement by oncogenic KRAS.";

McCormick F.

Cell Rep. 22:1889-1902(2018).

Pharmacoproteomic characterisation of human colon and rectal cancer.

Weichert W., Knapp S., Feller S.M., Kuster B.

Mol. Syst. Biol. 13:951-951(2017).

Genomic determinants of protein abundance variation in colorectal cancer cells.

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Choudhary J.S.

Cell Rep. 20:2201-2214(2017).

Characterization of human cancer cell lines by reverse-phase protein arrays.

Liang H.

Cancer Cell 31:225-239(2017).

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.

Golub T.R., Root D.E., Hahn W.C.

Sci. Data 1:140035-140035(2014).

The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets.

Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.

Nat. Commun. 6:7002.1-7002.10(2015).

A resource for cell line authentication, annotation and quality control.

Neve R.M.

Nature 520:307-311(2015).

A comprehensive transcriptional portrait of human cancer cell lines.

Settleman J., Seshagiri S., Zhang Z.-M.

Nat. Biotechnol. 33:306-312(2015).

Colorectal cancer cell lines are representative models of the main molecular subtypes of primary cancer.

Mariadason J.M., Sieber O.M.

Cancer Res. 74:3238-3247(2014).

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

5-fluorouracil response in a large panel of colorectal cancer cell lines is associated with mismatch repair deficiency.

Bracht K., Nicholls A.M., Liu Y., Bodmer W.F.

Br. J. Cancer 103:340-346(2010).

A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.

Haber D.A.

Cancer Res. 70:2158-2164(2010).

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

Cell growth, global phosphotyrosine elevation, and c-Met phosphorylation through Src family kinases in colorectal cancer cells.

Emaduddin M., Bicknell D.C., Bodmer W.F., Feller S.M.

Proc. Natl. Acad. Sci. U.S.A. 105:2358-2362(2008).

Analysis of p53 mutations and their expression in 56 colorectal cancer cell lines.

Liu Y., Bodmer W.F.

Proc. Natl. Acad. Sci. U.S.A. 103:976-981(2006).

APC mutations in sporadic colorectal tumors: a mutational 'hotspot' and interdependence of the 'two hits'.

Papadopoulou A., Bicknell D.C., Bodmer W.F., Tomlinson I.P.M.

Proc. Natl. Acad. Sci. U.S.A. 97:3352-3357(2000).

Production of hybrid cells by fusion of human malignant tumour cells and primary mouse embryo cells.

Watkins J.F.

Int. J. Cancer 20:535-542(1977).

Properties of a cell line from human adenocarcinoma of the rectum.";

Watkins J.F., Sanger C.

Br. J. Cancer 35:785-794(1977).